Hadziyannis, Stephanos J.

Publishing since 1980 (Dinosaur)

Has published 108 publications in 31 years

Number of publications published per year by Hadziyannis, Stephanos J.. (Source : PubMed)

Distribution of publications types for Hadziyannis, Stephanos J.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.  Hepatology  2010;51;2  
•  Reddy KR, Messinger D, Popescu M, Hadziyannis SJ. Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.  J. Viral Hepat.  2009;16;10  
•  Vassilopoulos D, Rapti I, Nikolaou M, Hadziyannis E, Hadziyannis SJ. Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B.  J. Viral Hepat.  2008;15;11  
•  Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.  Am. J. Gastroenterol.  2008;103;8  
•  Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.  J. Viral Hepat.  2008;15;2  
•  Sevastianos VA, Hadziyannis SJ. Nonalcoholic fatty liver disease: from clinical recognition to treatment.  Expert review of gastroenterology & hepatology  2008;2;1  
•  Hadziyannis SJ, Vassilopoulos D. Telbivudine in the treatment of chronic hepatitis B.  Expert review of gastroenterology & hepatology  2008;2;1  
•  Snoeck E, Hadziyannis SJ, Puoti C, Swain MG, Berg T, Marcellin P, Zarski JP, Jorga K, Zeuzem S. Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.  Liver Int.  2008;28;1  
•  Deutsch M, Papatheodoridis GV, Tzakou A, Hadziyannis SJ. Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis.  Eur J Gastroenterol Hepatol  2008;20;1  
•  Deutsch M, Hadziyannis SJ. Old and emerging therapies in chronic hepatitis C: an update.  J. Viral Hepat.  2008;15;1  

[ See timeline ] [ See all publications ]